Safety and immunogenicity of the third COVID-19 vaccines booster dose in children (12-18 years) with completed 2 doses as recommended by the ministry of public health

Phase 3

• Conditions: Health adolescents; COVID-19, booster, vaccine

• Registration Number: TCTR20221215006
• Lead Sponsor: Chulalongkorn University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-12-15
• Study Completion: 2023-02-28
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: nknown
• Sex: All
• Target Recruitment: 320

Inclusion Criteria

1. Healthy adolecents (aged between 12-18 years) who have previously received two doses following the ministry of public health (official proof of vaccinations required).
2. Have received your second dose of COVID-19 vaccine more than 3 months.
3. Have or Have not previously had COVID-19 infection.
4. are not in immunocompromised states (chronic diseases or immunodeficiency disorder)
5. No oallergies to the vaccine components
6. Are available for follow-ups and blood draws

Exclusion Criteria

1. Immunodeficiency status
2. Do not agree to participate
3. Severe coagulopathy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
immunogenicity 1 month neutralizing antibody against BA.5

Secondary Outcome Measures

Name	Time	Method
safety 1 month Frequency of adverse events